Yuang Wei
Overview
Explore the profile of Yuang Wei including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
130
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bu H, Song Q, Zhang J, Wei Y, Liu B
Anal Cell Pathol (Amst)
. 2024 Sep;
2023:2533992.
PMID: 39282155
Background: Clear cell renal cell carcinoma (ccRCC) accounts for more than 80% of renal cell carcinomas. Yet, it has not been fully understood about the derivation and progression of the...
2.
Wang B, Wei Y, Han T, Ji P, Miao H, Wu X, et al.
Eur J Med Res
. 2024 Feb;
29(1):103.
PMID: 38326905
Background: Long non-coding RNAs (lncRNAs) have been extensively investigated in the field of cancer, among which, lncRNA ladybird homeobox 2-antisense RNA 1 (LBX2-AS1) has been demonstrated to exert carcinogenic effects...
3.
Zhang J, Chen C, Wei Y, Chen L, Shao P, Xu H
Zhonghua Yi Xue Yi Chuan Xue Za Zhi
. 2024 Feb;
41(2):150-156.
PMID: 38311552
Objective: To assess the prognostic value of methylation of interferon regulatory factor 6 (IRF6) gene promoter in patients diagnosed with Kidney renal clear cell carcinoma (KIRC). Methods: The primary lesions...
4.
Chen X, Zhang T, Ren X, Wei Y, Zhang X, Zang X, et al.
Eur J Med Res
. 2023 Dec;
28(1):588.
PMID: 38093375
Targeted therapy is pivotal in renal carcinoma treatment, and the dual-inhibitor NVP-BEZ235 has emerged as a promising candidate in preliminary studies. Its effectiveness against renal carcinoma and the mechanisms underlying...
5.
Wei Y, He H, Han T, Wang B, Ji P, Wu X, et al.
Ecotoxicol Environ Saf
. 2023 Jul;
263:115267.
PMID: 37499384
Perfluorinated compounds (PFCs) are man-made chemicals used in the manufacture of many products with water and dirt repellent properties. Many diseases have been proved to be related to the exposure...
6.
Zhang D, Xu X, Wei Y, Chen X, Li G, Lu Z, et al.
Cancer Control
. 2022 Oct;
29:10732748221129451.
PMID: 36283420
Objective: Evidence shows that gene mutation is a significant proportion of genetic factors associated with prostate cancer. The DNA damage response (DDR) is a signal cascade network that aims to...
7.
Wang B, Song Q, Wei Y, Wu X, Han T, Bu H, et al.
Front Immunol
. 2022 Oct;
13:948042.
PMID: 36275737
Background: Copper-induced cell death has been widely investigated in human diseases as a form of programmed cell death (PCD). The newly recognized mechanism underlying copper-induced cell death provided us creative...
8.
Wu J, Wei Y, Miao C, Wang S, Wang X, Wang Z
J Oncol
. 2022 May;
2022:9411692.
PMID: 35502201
mA RNA modification is a common abundant posttranscriptional modification of mRNAs occurring in cancer growth and progression. Accumulated evidence has proved that HNRNPC, which acts as a mA reader, plays...
9.
Liu Y, Wang J, Li L, Qin H, Wei Y, Zhang X, et al.
Sci Rep
. 2022 Mar;
12(1):4272.
PMID: 35277527
Extensive research indicates that tumor stemness promotes tumor progression. Nonetheless, the underlying roles of stemness-related genes in renal clear cell carcinoma (ccRCC) are unclear. Data used in bioinformatics analysis were...
10.
Wei Y, Chen X, Ren X, Wang B, Zhang Q, Bu H, et al.
Front Genet
. 2021 Jul;
12:680369.
PMID: 34306023
Background: Antiangiogenic agents that specifically target vascular endothelial growth factor receptor (VEGFR), such as sunitinib, have been utilized as the standard therapy for metastatic clear cell renal cell carcinoma (ccRCC)...